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1025-44 Is the ICHOR Platelet Works Test as Valid as Flow 
Cytometry to Assess the Efficacy of Platelet 
Glycoprotein IIb/IIIa-Receptor Inhibitors in Patients 
Undergoing Percutaneous Coronary Intervention?
Jochem W. van Werkum, Wim BM Gerritsen, Hans C. Kelder, Fred JLM Haas, Jurriën M. 
ten Berg, Sint Antonius Hospital, Nieuwegein, The Netherlands
Background
Inhibition of the glycoprotein (GP) IIb/IIIa receptor on platelets by tirofiban and abciximab
has shown to reduce ischemic complications in patients undergoing elective percutane-
ous coronary intervention (PCI). The effect of GP IIb/IIIa antagonists can be measured by
flowcytometry, but it is a labour intensive and expensive method. The ICHOR platelet-
works is a quick and inexpensive method for measuring platelet aggregation. The ICHOR
method determines a reference platelet count in 1 ml blood in a tube containing K3-EDTA
as the anticoagulant. This process is repeated with a second tube with blood containing
20 µmol/L ADP. In the presence of ADP, platelets associate and aggregate. The ratio
between the numbers of platelets in the two tubes that did not aggregate is calculated as
percent platelet aggregation. The purpose of this study was to compare the results of
these two methods in patients treated with abciximab or tirofiban.
Methods
We randomised 40 AMI patients to abciximab (Group A, N=20) and to tirofiban ( GroupB,
N=20). Before, immediately after, 30 minutes after, 60 minutes after and 120 minutes
after PCI, bloodsamples were obtained and tested with the ICHOR test (platelet aggrega-
tion) and with flowcytometry (Biotex GP IIb/IIIa receptor occupancy kit). Correlation was
tested between the median values of flowcytometry and the ICHOR test for abciximab
and tirofiban with the use of Pearsons correlation.
Results
In Group A, GP IIb/IIIa receptor occupancy was at the different time points respectively:
0%, 86%, 90 %, 87 % and 88% and platelet aggregation was respectively: 63%, 31%,
40%, 43% and 52%. In Group B, GP IIb/IIIa receptor occupancy was at the different time
points respectively: 0%, 60%, 56%, 51% and 51% and platelet aggregation was respec-
tively: 68%, 77%, 77%, 80% and 81%.
No significant correlation between GP IIb/IIIa receptor-occupancy and platelet aggrega-
tion was found between both groups at the different time points. (Abciximab: r =0,090;
tirofiban: r =-0,031)
Conclusion
As compared with “the gold standard” flowcytometry, the ICHOR plateletworks method is
not useful to monitor de level of GP IIb/IIIa-receptor occupancy in patients treated with
abcixmab or tirofiban.
1025-45 Preprocedural Statin Medication Reduces Small and 
Large Periprocedural Myocardial Injury in Patients With 
Stent Implantation
Michael Haude, Joerg Herrmann, Lothar Volbracht, Thomas Konorza, Christoph 
Altmann, Rainer Schulz, Gerd Heusch, Raimund Erbel, University Hospital Essen, 
Essen, Germany, Mayo Clinic, Rochester
Background: Stenting-related myocardial injury (MI) is caused by microembolisation of
platelet aggregates and plaque debris together with inflammation. The pleiotropic effects
of HMG-CoA reductase inhibitors (statins) include anti-thrombotic and anti-inflammatory
aspects. Thus, we tested whether pre-procedural statin therapy limits the extent of peri-
procedural MI.
Methods: We stratified 1218 consecutive patients (pts)with uncomplicated stenting
according to their pre-procedural status of statin therapy (1012 statin-pos. and 206 statin-
neg. pts). Peri-procedural MI was assessed by analysis of creatine kinase (CK; upper
limit of normal (ULN) 80 IU/l), CK-MB (threshold ULN >8% of CK fraction) and cardiac
troponin I (TI; threshold 0.1 mg/L) before, 6, 12, and 24 hours after the intervention.
Results: Baseline characteristics including lipid levels were similar between statin-pos.
and statin-neg. pts. Postinterventional maximum CK, CK-MB, and TI elevations were
larger in statin-neg. pts (68±62 vs 52±46 IU/L; 24±20 vs 18±18 IU/L; and 0.46±0.48 vs
0.38±0.42mg/L; all p<0.001). Statin pretreatment reduced the relative risk for MI for all
cut-off criteria separating small, intermediate and large MI.
Conclusions: Pre-procedural statin therapy reduces stenting-related MI independent of
the ischemia marker and the cut-off levels with relative risk reductions (RRR)ranging 30
to 75%. 
1025-46 Prior Statin Therapy Reduces Myocardial Injury in 
Patients Undergoing Rotational Atherectomy
Edward J. McNulty, Gary Spektor, Eric Chou, Manish Parikh, Robert Minutello, Geoffrey 
Bergman, Frank Iacovone, Mun K. Hong, S. Chiu Wong, Weill Cornell Medical Center, 
New York, NY
Background: Extensive microembolization occurs during rotational atherectomy (RA),
which contributes to high rates of post-procedure cardiac enzyme elevation. We hypothe-
sized that statin therapy might ameliorate the deleterious effects of microembolization
during RA and reduce post-procedural enzyme elevations.
Methods: We studied 230 consecutive patients who underwent coronary interventions
utilizing RA between September 2000 and April 2003. Patients with renal insufficiency or
with elevated cardiac troponin I (cTnI) or creatinine kinase (CK) prior to RA were
excluded. Baseline, procedural, and post-procedural outcomes were compared for those
patients on statin therapy prior to RA and for those not on statin therapy.
Results: Baseline characteristics were similar between the two cohorts. There was no
significant difference in the use of stents or IIb/IIIa inhibitors. Patients on statin therapy
had significant reductions in mean peak cTnI and in the rate of elevated cTnI (> 1.5 ng/
ml) following the procedure. On multivariate analysis, lack of statin therapy was the only
independent predictor of cTnI elevation. 
Conclusions: Patients on statin therapy prior to RA had a nearly 50% reduction in the 
rate elevated cTnI post-procedure. Statin therapy maintained its cardioprotective effect 
even though the majority of patients received IIb\IIIa inhibitors during the procedure. 
These results further demonstrate the cardioprotective effect of statins in coronary inter-
ventions.
1025-63 Acute and Early Changes in Plasma Vascular Growth 
Factors and Circulating Endothelial Progenitor Cells in 
Patients With Acute ST Elevation Myocardial Infarction
Yongzhong Wang, Hans E. Johnsen, Erik Jørgensen, Jens Kastrup, Rigshospitalet, 
Copenhagen, Denmark, Herlev Hospital, Copenhagen, Denmark
Background: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
(bFGF) show strong angiogenic effects in ischemic myocardium. Circulating bone mar-
row-derived endothelial progenitor cells (EPCs) can augment neovascularization in
ischemic tissue. We evaluated their roles for myocardial repair in patients with acute ST-
elevation myocardial infarction (STEMI).
Methods: Circulating EPCs and plasma VEGF/bFGF levels were examined in 20 STEMI
patients undergoing percutaneous coronary intervention within 12h of the symptoms.
Blood samples were obtained within the initial 24h after admission and day 3,7,14,21 and
28. 15 age and sex-matched individuals with angina, but with normal coronary angiogra-
phy, were included as controls.
Results: Plasma VEGF levels decreased approximately 50% within the initial 24 hours
and increased to a level twice the level in controls two weeks after STEMI. The plasma
bFGF levels and circulating EPCs at different time points after admission were not signif-
icantly different from the controls. However, within the patients with STEMI, plasma bFGF
level (pg/ml) increased on day 7, 14, 21 and 28 compare to day 1 on admission (P<0.05
for all).
Conclusion: The elevated plasma VEGF and bFGF levels in the subacute phase after
acute STEMI might be an indicator of the initiation of restoring angiogenesis in the inf-
arcted myocardium. No cardiac signal seems to initiate the mobilization of stem cells
from the bone marrow for vasculogenesis in the infarcted myocardium.
Not on Statin Therapy 
(N= 83 )
On Statin Therapy
(N= 147)
P Value
Patient Characteristics
Diabetes 21 % 25 % .42
Prior CABG 15 % 22 % .14
Unstable Angina 31 % 37 % .35
Procedural Findings
New Stent Placed 65 % 70 % .43
IIb\IIIa Inhibitor use 81 % 79% .74
Outcomes
cTnI Elevation 47% 26% .001
Mean Peak cTnI (ng/ml) 3.7 ± 7.4 1.8 ± 4.3 .01
CK Elevation 9.6% 4.8% .15
